ADMA BIOLOGICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ADMA BIOLOGICS, INC. (ADMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.00 per share for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2017-02-24
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-03-31 was $7.56.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $5.25, a 3.75% increase from fiscal 2014.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2014 was $5.06, a 16.32% increase from fiscal 2013.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2013 was $4.35, a 18.99% decline from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-24 | ||||
| 2015-12-31 | $5.25 10-K · filed 2017-02-24 | ||||
| 2014-12-31 | $5.06 10-K · filed 2016-03-23 | ||||
| 2013-12-31 | $4.35 10-K · filed 2015-03-09 | ||||
| 2013-09-30 | $4.42 10-Q · filed 2013-11-12 | ||||
| 2013-03-31 | $7.56 10-Q · filed 2013-05-14 | ||||
| 2012-12-31 | $5.37 10-K · filed 2014-03-28 | $6.82 10-K · filed 2013-03-06 | |||
| 2012-09-30 | $6.82 10-Q · filed 2012-11-13 | ||||
| 2012-06-30 | $6.80 10-Q · filed 2012-08-14 | ||||
| 2011-12-31 | $0.00 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |